Catalyst Pharmaceutical Partners to Present at The Roth Capital Partners 2007 New York Conference
CORAL GABLES, Fla., Aug. 29 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. a specialty pharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, today announced that Patrick J. McEnany, President and Chief Executive Officer, will be presenting an overview of the Company at the Roth Capital Partners 2007 New York Conference on Wednesday, September 5th at the Westin New York at Times Square hotel in New York City. Mr. McEnany's presentation is scheduled for 1:00pm ET.
The presentation will be webcast live and can be accessed at www.wsw.com/webcast/roth13/cprx/. An archived recording of the presentation will be available for 90 days following the event.
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents and four patents pending in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. Catalyst recently initiated a 180 patient randomized, double- blind, placebo-controlled, multi-center U.S. Phase II clinical trial of CPP- 109 in patients with cocaine addiction and expects to initiate a similar trial in patients with methamphetamine addiction later this year.
For more information about the Company, go to www.catalystpharma.com.
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in the Company's Annual Report on Form 10-K for 2006 and the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 that the Company has filed with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.Catalyst Pharmaceutical Partners, Inc.
CONTACT: Jack Weinstein, Chief Financial Officer of CatalystPharmaceutical Partners, Inc., +1-201-934-4201,email@example.com; or Melody Carey of Rx Communications Group,+1-917-322-2571, firstname.lastname@example.org, for Catalyst Pharmaceutical Partners,Inc.